Fortis Inc/ CA3495531079 /
| 9/17/2024 10:10:00 PM | Chg. -0.31 | Volume | Bid2:00:00 AM | Ask2:00:00 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 45.34USD | -0.68% | 406,747 Turnover: 13.57 mill. |
44.70Bid Size: 100 | 46.41Ask Size: 100 | 22.25 bill.USD | - | - |
GlobeNewswire
8/6
FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
7/23
Advisory: Fortis Inc. to Hold Teleconference on July 31 to Discuss Second Quarter 2024 Results
GlobeNewswire
7/2
Fortis Inc. to Hold Teleconference on July 31 to Discuss Second Quarter 2024 Results
GlobeNewswire
6/18
FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program ...
GlobeNewswire
6/10
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annu...
GlobeNewswire
5/23
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) ...
GlobeNewswire
5/15
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
GlobeNewswire
4/24
Advisory: Fortis Inc. to Hold Teleconference on May 1 to Discuss First Quarter 2024 Results and Hold...
GlobeNewswire
4/24
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combinat...
GlobeNewswire
4/23
Maryland CareerQuest Connects Area Students with Training and Education Opportunities for Hands-On C...
GlobeNewswire
4/3
Fortis Inc. to Hold Teleconference on May 1 to Discuss First Quarter 2024 Results and Hold Annual an...
GlobeNewswire
4/2
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metast...
GlobeNewswire
3/28
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ...
GlobeNewswire
3/19
AstriVax Rounds Out Executive Team with Chief Business Officer (CBO) Dr. Gregory Fanning
